New clinical trials recently added to the National Cancer Institute's database
BLADDER CANCER
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: PC B308/13, NCI-2015-01925, NCT02560584
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BOND 2 version 3.5, NCI-2015-01830, BOND 2 version 3.4, NCT02365818
Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-126, NCI-2015-01786, NCT02553642
BRAIN/CNS TUMORS
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ICT-107-301, NCI-2015-01811, NCT02546102
Hippocampal-Avoiding Whole-Brain Radiotherapy with Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy in Treating Patients with Brain Metastases
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: STU 042011-050, NCI-2015-01675, NCI-2014-01736, NCI-2014-02008, NCT01414738
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: NMTRC010, NCI-2015-01871, NCT02139397
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: NMTRC 003, NCI-2014-02153, NCI-2014-00474, NCT01586260
Radiosurgery in Treating Patients With Brain Metastases
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 1306012291, NCI-2013-01986, NCT02005614
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
BREAST CANCER
Taselisib and Enzalutamide in Treating Patients with Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC BRE 1374, NCI-2015-00795, BRE 1374, BRE 1374 / TBCRC 032, GO28972, TBCRC 032, NCT02457910
Palbociclib in Combination with Fulvestrant or Tamoxifen Citrate in Treating Patients with Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 147522, NCI-2015-01791, CC#147522, TBCRC035, NCT02384239
Talazoparib in Treating Patients with BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BRS0050, NCI-2015-00036, 350, NCT02401347
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Locally Advanced or Inflammatory Triple Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11174, NCI-2012-00025, 103352, 109696, 110312, 118191, NCT01525966
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2076-CL-005, NCI-2013-00059, NCT01639248
CERVICAL CANCER
A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348
COLORECTAL CANCER
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13050, NCI-2015-01790, NCT02425683
GI CANCERS
Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS001-06, NCI-2015-01897, NCT02399813
Docetaxel, Cisplatin, and Fluorouracil in Treating Patients with Gastric or Gastroesophageal Junction Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 06-103, NCI-2015-01798, NCT00515411
HEAD & NECK/ORAL CANCER
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D4193C00002, NCI-2015-01842, NCT02369874
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: IOM-HNC-201-IL, NCI-2015-01924, NCT01400620
Radiation Therapy and Pembrolizumab in Treating Patients with Head and Neck Squamous Cell Carcinoma That Is Recurrent or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1456GCC, NCI-2015-01783, HP-00061458, NCT02289209
Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-CR-602, NCI-2015-01845, NCT02449681
Paclitaxel Albumin-Stabilized Nanoparticle Formulation with Cisplatin or Cetuximab in Treating Patients with Stage III-IVb Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201510013, NCI-2015-01775, NCT02573493
KIDNEY CANCER
Ixazomib Citrate and Peginterferon Alfa-2b in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GU-071, NCI-2015-01878, ERP GU-071, NCT02447887
LEUKEMIA/LYMPHOMA/MDS
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17067, NCI-2015-01865, 2013-003893-29, NCT02367040
Azacitidine and Lenalidomide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: 12-1283, NCI-2012-03191, 12-1283.cc, RV-AML-PI-0759, NCT01743859
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLBH589H2101, NCI-2010-00116, 2009-010548-32, NCT00946647
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride with Asparaginase in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9459, NCI-2015-01402, CC9459, NCT02538926
Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small Lymphocytic Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-313-1580, NCI-2015-01816, 2015-000366-66, NCT02536300
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-025, NCI-2015-01867, NCT02572167
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Phase: Phase III
Type: Treatment
Age: 18 to 79
Trial IDs: Onconova 04-30, NCI-2015-01849, 2015-001476-22, NCT02562443
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Phase: Phase III
Type: Treatment
Age: 60 and over
Trial IDs: AG-221-AML-004, NCI-2015-01945, NCT02577406
Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Phase: Phase II, Phase I
Type: Treatment
Age: 45 and under
Trial IDs: NYMC 564, NCI-2015-01809, NCT02098512
A Phase 1/2, Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ASN002-101, NCT02440685
Lenalidomide and High-Dose Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory, Diffuse Large B-Cell Lymphoma of the ABC Subtype
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 65
Trial IDs: 2015-0558, NCI-2015-01938, NCT02589145
Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and under
Trial IDs: TINI, NCI-2015-01493, NCT02553460
Ibrutinib and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0090, NCI-2013-01304, NCT01880567
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BL-8040.06, NCI-2015-01892, NCT02462252
LUNG CANCER/MESOTHELIOMA
A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower 111]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29432, NCI-2015-01801, NCT02409355
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCRN LUN14-179, NCI-2015-01808, NCT02343952
A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-451, NCI-2015-01840, NCT02538666
Irinotecan Hydrochloride in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INST 1201, NCI-2012-01531, 12-097, NCT01607554
Nivolumab after Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA5142, NCI-2015-01916, NCT02595944
Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-CR-601, NCI-2015-01844, NCI-2015-01843, NCT02454842
A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CO-1686-033, NCI-2015-01854, NCT02580708
MELANOMA/SKIN CANCER
Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-CR-602, NCI-2015-01845, NCT02449681
Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-126, NCI-2015-01786, NCT02553642
MYELOMA
Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-183, NCI-2015-01850, 2015-002509-13, NCT02576977
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: BMTCTN1302, NCI-2015-01829, U01HL069294-05, NCT02440464
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-185, NCI-2015-01851, 2015-002901-12, NCT02579863
Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140
Pembrolizumab, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1454GCC, NCI-2015-01784, GCC1454 / HP-00061522, HP-00061522, HCR-HP-00061522-1, NCT02289222
Monoclonal Antibody Therapy and Vaccine Therapy after Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-061, NCI-2010-01326, NCT01067287
OVARIAN CANCER
A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348
PANCREATIC CANCER
Cabozantinib-s-Malate in Treating Patients with Advanced Pancreatic Neuroendocrine or Carcinoid Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-274, NCI-2012-00539, NCT01466036
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: 1306012255, NCI-2013-02349, NCT02047474
Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18141, NCI-2015-01782, 15.04.0041, NCT02575300
PROSTATE CANCER
Diet and Exercise Program in Promoting Weight Loss and Improving Health in Patients with Low- or Low-Intermediate-Risk Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Age: 40 to 75
Trial IDs: 9369, NCI-2015-00686, NCT02454517
Best Systemic Therapy with or without Radiation Therapy or Surgery in Treating Patients with Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0705, NCI-2013-00415, NCT01751438
Ribociclib, Docetaxel. and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 145515, NCI-2015-01797, 15-15745, CLEE011XUS07T, NCI-2015-01701, NCT02494921
Sipuleucel-T and Stereotactic Ablative Body Radiation Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 102012-026, NCI-2015-01669, NCT01818986